Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

The Longitudinal Cohort of Cerebral Small Vessel Disease in Ruijin Hospital

21 luglio 2026 aggiornato da: Ruijin Hospital

The goal of this observational study is to learn about neuroimage and biomarkers in the cerebral small vessel disease. The main questions it aims to answer are:

How does neurovascular coupling change during the progression of CSVD?
How is the pattern/mapping of alterations in CSVD biomarkers? Participants will be observed and visit the research center annually to perform multi-modal MRI, PET, neuropsychological tests, and blood tests.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Malattia cerebrale dei piccoli vasi

Descrizione dettagliata

This observational study recruits participants with cerebral small vessel disease (CSVD) from hospitals and community-based populations. Healthy volunteers will also be recruited as controls. Longitudinal follow-up of these participants will help clarify the significance of neuroimaging and biological biomarkers during the development and progression of CSVD.

The investigators aim to establish a longitudinal cohort covering the spectrum of CSVD and identify key biomarkers associated with disease progression and cognitive decline. All participants will undergo multimodal MRI, PET imaging (optional) with different tracers, and blood biomarker assessments. Using multimodal MRI, the investigators will investigate alterations in neurovascular coupling and their role in the pathophysiology of CSVD. In addition, PET imaging (optional) and blood biomarkers will be used to characterize the spatial and temporal patterns of disease-related biomarker changes. Furthermore, additional neuroimaging and digital biomarkers will be evaluated within the cohort to improve disease characterization and prognostic prediction.

Tipo di studio

Osservativo

Iscrizione (Stimato)

400

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

Cina
- Shanghai Municipality
  - Shanghai, Shanghai Municipality, Cina, 200025
    - Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    - Contatto:
      
      Jingyan Tian, Dr
      
      Numero di telefono: 13671865057
      
      Email: tjy11488@rjh.com.cn
    - Investigatore principale:
      
      Jingwen Jiang, Dr.
    - Sub-investigatore:
      
      Binyin Li, Dr.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Adulto
Adulto più anziano

Accetta volontari sani

Sì

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The population consists of vascular dementia, vascular mild cognitive impairment, and cognitively normal participants.

Descrizione

Inclusion Criteria:

Age ≥18 years.
Evidence of cerebral small vessel disease (CSVD) on brain MRI, meeting at least one of the following imaging criteria:
- White matter hyperintensities (WMH) with a total Fazekas score ≥2;
- Fazekas score =1 with at least two vascular risk factors (hypertension, hyperlipidemia, diabetes mellitus, obesity, current smoking, or a history of vascular events other than stroke);
- Fazekas score =1 accompanied by the presence of lacunes;
- Imaging evidence of a recent subcortical lacunar infarction.
Independent in activities of daily living (modified Rankin Scale [mRS] ≤2).
Able and willing to provide written informed consent.

Exclusion Criteria:

Acute ischemic stroke with a diffusion-weighted imaging (DWI) lesion >20 mm in diameter.
Acute intracerebral hemorrhage.
Acute subarachnoid hemorrhage, a history of aneurysmal subarachnoid hemorrhage or cerebrovascular malformation, or the presence of an untreated intracranial aneurysm >3 mm in diameter.
Previously diagnosed neurodegenerative disorders, such as Alzheimer's disease (AD) or Parkinson's disease (PD).
Definite non-vascular white matter diseases, including multiple sclerosis, adult-onset leukodystrophy, metabolic encephalopathy, or other non-vascular white matter disorders.
Major psychiatric disorders diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
Contraindications to MRI (e.g., severe claustrophobia or MRI-incompatible implants).
Severe systemic diseases (e.g., active malignancy) with an expected life expectancy of less than 5 years.
Inability to complete scheduled follow-up because of geographic, logistical, or other reasons.
Concurrent participation in another interventional clinical trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Numero di gruppi/coorti

Coorti e interventi

Gruppo / Coorte
Cognitively Normal Participants do not have cognitive impairment.
Cerebral small vessel disease without dementia Participants have vascular cognitive impairment, but no cognitive impairment
Vascular Dementia (VaD) Participants have vascular cognitive impairment or difficulty in daily activity.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato	Misura Descrizione	Lasso di tempo
Global cognitive ability Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Mini-mental state examination	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Executive function Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Clock drawing test	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Visual memory Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Rey-Osterich complex figure test	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Short-term memory Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Auditory verbal learning test	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Executive memory Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Symbol-digit test	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Spatial executive function Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Trail making test	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Naming ability Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Boston naming test	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Language ability Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Language fluency test	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Sleep quality Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Sleep disorder	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Movement ability Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Part III of the Unified Parkinson's Disease Rating Scale	baseline, 1 year, 2-year, 3-year, 5-year,10-year

Misure di risultato secondarie

Misura del risultato	Misura Descrizione	Lasso di tempo
Brain volume Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Annual changes of volumes of brain	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Connectivity integrity of the neural circuit Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Annual changes of hippocampus related neural connectivity	baseline, 1 year, 2-year, 3-year, 5-year,10-year
Volume of white matter lesions Lasso di tempo: baseline, 1 year, 2-year, 3-year, 5-year,10-year	Structural and functional MRI measures, including arterial spin labeling (ASL), diffusion MRI (dMRI), susceptibility-weighted imaging (SWI) and fluid-attenuated inversion recovery (FLAIR).	baseline, 1 year, 2-year, 3-year, 5-year,10-year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Ruijin Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

8 luglio 2026

Completamento primario (Stimato)

30 settembre 2028

Completamento dello studio (Stimato)

31 dicembre 2028

Date di iscrizione allo studio

Primo inviato

10 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

21 luglio 2026

Primo Inserito (Effettivo)

24 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)